Celiac disease prevalence rises in Finland as research highlights need for awareness and treatment
In Finland, the prevalence of celiac disease is among the highest worldwide, and recent research indicates that its incidence is on the rise. According to researchers at the University of Tampere, approximately 2.4% of the Finnish population is affected, compared to a global prevalence of around 1.4%. In 2000, the prevalence in Finland was estimated to be 2.1%.
Despite widespread awareness of the condition, the Celiac Society estimates that around 70,000 Finns may be undiagnosed. Celiac disease occurs when gluten, found in certain grain products, damages the intestinal lining and causes inflammation. Some patients also experience skin symptoms. The disease tends to affect individuals with a hereditary predisposition, influenced by various genes and likely aggravated by enterovirus infections in childhood.
Currently, there is no cure for celiac disease, and the only treatment is a strict lifelong gluten-free diet. Symptoms can include diarrhea, stomach pain, bloating, gas, and constipation, with untreated celiac disease leading to osteoporosis, a severe long-term consequence.
Research is ongoing for potential treatments, including the experimental drug ZED1227, which has shown promise in preventing the enzyme that triggers the disease mechanism in the intestine. Administered orally, the medication demonstrated effects lasting up to 24 hours post-ingestion.
In future phases of clinical trials, the study will include a broader patient population, including individuals from Finland. While promising, experts note that this medication does not guarantee that celiac patients can consume gluten-containing products like rye bread without concern. Dietary management will remain a critical aspect of treatment. Government considerations for compensation policies aimed at affected populations are also in the pipeline, emphasizing support for minors and low-income adults.